Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Receivables (2020 - 2025)

Vivos Therapeutics' Change in Receivables history spans 6 years, with the latest figure at -$553000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at -$553000.0 for Q4 2025, down 2204.17% from a year ago — trailing twelve months through Dec 2025 was $217000.0 (down 4.82% YoY), and the annual figure for FY2025 was $217000.0, down 4.82%.
  • Change in Receivables for Q4 2025 was -$553000.0 at Vivos Therapeutics, down from $501000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.8 million in Q2 2021 to a low of -$2.6 million in Q4 2021.
  • The 5-year median for Change in Receivables is -$21500.0 (2024), against an average of -$39200.0.
  • The sharpest move saw Change in Receivables skyrocketed 4626.55% in 2021, then plummeted 2283.33% in 2024.
  • Year by year, Change in Receivables stood at -$2.6 million in 2021, then skyrocketed by 84.45% to -$409000.0 in 2022, then soared by 93.64% to -$26000.0 in 2023, then grew by 7.69% to -$24000.0 in 2024, then tumbled by 2204.17% to -$553000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$553000.0, $501000.0, and -$19000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.